| __timestamp | Bausch Health Companies Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 5078000000 |
| Thursday, January 1, 2015 | 2682700000 | 4717000000 |
| Friday, January 1, 2016 | 2810000000 | 5096000000 |
| Sunday, January 1, 2017 | 2582000000 | 4986000000 |
| Monday, January 1, 2018 | 2473000000 | 4214000000 |
| Tuesday, January 1, 2019 | 2554000000 | 3806000000 |
| Wednesday, January 1, 2020 | 2367000000 | 3671000000 |
| Friday, January 1, 2021 | 2624000000 | 3528000000 |
| Saturday, January 1, 2022 | 2625000000 | 3445000000 |
| Sunday, January 1, 2023 | 2917000000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Bausch Health Companies Inc. from 2014 to 2023. Over this period, Teva consistently reported higher SG&A expenses, peaking in 2016 with a 20% lead over Bausch. However, a notable decline of approximately 32% was observed by 2023, reflecting strategic cost management or market challenges. Conversely, Bausch's expenses remained relatively stable, with a slight increase of around 44% from 2014 to 2023, indicating steady operational costs. This financial snapshot not only highlights the contrasting fiscal strategies of these companies but also offers insights into their market positioning and adaptability in a competitive landscape.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited
SG&A Efficiency Analysis: Comparing Teva Pharmaceutical Industries Limited and Ascendis Pharma A/S
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Bausch Health Companies Inc.
Insmed Incorporated or Bausch Health Companies Inc.: Who Manages SG&A Costs Better?
Ascendis Pharma A/S or Bausch Health Companies Inc.: Who Manages SG&A Costs Better?
Grifols, S.A. vs Bausch Health Companies Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Who Optimizes SG&A Costs Better? Bausch Health Companies Inc. or Supernus Pharmaceuticals, Inc.